

# Christian Gachet

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7804886/publications.pdf>

Version: 2024-02-01

110  
papers

7,351  
citations

50276

46  
h-index

56724

83  
g-index

114  
all docs

114  
docs citations

114  
times ranked

6674  
citing authors

#	ARTICLE	IF	CITATIONS
1	Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y1 receptor null mice. <i>Journal of Clinical Investigation</i> , 1999, 104, 1731-1737.	8.2	393
2	ADP Receptors of Platelets and their Inhibition. <i>Thrombosis and Haemostasis</i> , 2001, 86, 222-232.	3.4	375
3	Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 85-92.	3.8	367
4	P2 receptors, platelet function and pharmacological implications. <i>Thrombosis and Haemostasis</i> , 2008, 99, 466-472.	3.4	250
5	The P2Y1 Receptor Is Necessary for Adenosine 5'-Diphosphate-Induced Platelet Aggregation. <i>Blood</i> , 1998, 92, 152-159.	1.4	247
6	REGULATION OF PLATELET FUNCTIONS BY P2 RECEPTORS. <i>Annual Review of Pharmacology and Toxicology</i> , 2006, 46, 277-300.	9.4	245
7	Mechanisms underlying FeCl <sub>3</sub> -induced arterial thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 779-789.	3.8	209
8	Platelet glycoprotein VI binds to polymerized fibrin and promotes thrombin generation. <i>Blood</i> , 2015, 126, 683-691.	1.4	203
9	A Role of the Fast ATP-gated P2X1 Cation Channel in Thrombosis of Small Arteries In Vivo. <i>Journal of Experimental Medicine</i> , 2003, 198, 661-667.	8.5	191
10	Megakaryocyte-restricted MYH9 inactivation dramatically affects hemostasis while preserving platelet aggregation and secretion. <i>Blood</i> , 2007, 110, 3183-3191.	1.4	158
11	Preparation of Washed Platelet Suspensions From Human and Rodent Blood. , 2004, 272, 013-028.		151
12	Update of P2Y receptor pharmacology: IUPHAR Review 27. <i>British Journal of Pharmacology</i> , 2020, 177, 2413-2433.	5.4	151
13	Purinergic Receptors in Thrombosis and Inflammation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 2307-2315.	2.4	141
14	Diagnosis of suspected inherited platelet function disorders: results of a worldwide survey. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1562-1569.	3.8	139
15	MRS2500 [2-Iodo-N <sup>6</sup> -methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate], a Potent, Selective, and Stable Antagonist of the Platelet P2Y1 Receptor with Strong Antithrombotic Activity in Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 316, 556-563.	2.5	135
16	Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors. <i>British Journal of Haematology</i> , 1995, 91, 434-444.	2.5	134
17	Key Role of the P2Y <sub>1</sub> Receptor in Tissue Factor-Induced Thrombin-Dependent Acute Thromboembolism. <i>Circulation</i> , 2001, 103, 718-723.	1.6	128
18	Differential Involvement of the P2Y <sub>1</sub> and P2Y <sub>12</sub> Receptors in Platelet Procoagulant Activity. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 1941-1947.	2.4	128

#	ARTICLE	IF	CITATIONS
19	Cardiovascular Mortality in Chronic Kidney Disease Patients Undergoing Percutaneous Coronary Intervention Is Mainly Related to Impaired P2Y <sub>12</sub> Inhibition by Clopidogrel. <i>Journal of the American College of Cardiology</i> , 2011, 57, 399-408.	2.8	121
20	Clopidogrel 150 mg/day to Overcome Low Responsiveness in Patients Undergoing Elective Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2008, 1, 631-638.	2.9	119
21	Desensitization of the Platelet Aggregation Response to ADP: Differential Down-regulation of the P2Y <sub>1</sub> and P2cyc Receptors. <i>Thrombosis and Haemostasis</i> , 2000, 84, 484-491.	3.4	118
22	P2Y <sub>12</sub> receptors in platelets and other hematopoietic and non-hematopoietic cells. <i>Purinergic Signalling</i> , 2012, 8, 609-619.	2.2	114
23	Biogenesis of the demarcation membrane system (DMS) in megakaryocytes. <i>Blood</i> , 2014, 123, 921-930.	1.4	112
24	The P2 Receptors in Platelet Function. <i>Seminars in Thrombosis and Hemostasis</i> , 2005, 31, 150-161.	2.7	111
25	P2 receptors and platelet function. <i>Purinergic Signalling</i> , 2011, 7, 293-303.	2.2	108
26	Immobilized fibrinogen activates human platelets through glycoprotein VI. <i>Haematologica</i> , 2018, 103, 898-907.	3.5	101
27	Signaling Role for Phospholipase C $\beta$ 2 in Platelet Glycoprotein Ib $\alpha$ Calcium Flux and Cytoskeletal Reorganization. <i>Journal of Biological Chemistry</i> , 2003, 278, 32880-32891.	3.4	94
28	Platelet integrin $\alpha$ 6 $\beta$ 1 controls lung metastasis through direct binding to cancer cell-derived ADAM9. <i>JCI Insight</i> , 2016, 1, e88245.	5.0	90
29	Integrin $\alpha$ 6 $\beta$ 1 Is the Main Receptor for Vascular Laminins and Plays a Role in Platelet Adhesion, Activation, and Arterial Thrombosis. <i>Circulation</i> , 2013, 128, 541-552.	1.6	85
30	A review of platelet secretion assays for the diagnosis of inherited platelet secretion disorders. <i>Thrombosis and Haemostasis</i> , 2015, 114, 14-25.	3.4	82
31	Presence of P2X <sub>1</sub> Purinoceptors in Human Platelets and Megakaryoblastic Cell Lines. <i>Thrombosis and Haemostasis</i> , 1997, 78, 1500-1504.	3.4	82
32	Major Contribution of the P2Y <sub>1</sub> Receptor in Purinergic Regulation of TNF $\alpha$ -Induced Vascular Inflammation. <i>Circulation</i> , 2011, 123, 2404-2413.	1.6	81
33	Reduced Atherosclerotic Lesions in P2Y <sub>1</sub> /Apolipoprotein E Double-Knockout Mice. <i>Circulation</i> , 2008, 118, 754-763.	1.6	76
34	Arterial thrombosis: relevance of a model with two levels of severity assessed by histologic, ultrastructural and functional characterization. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 173-184.	3.8	75
35	Time-Dependent Decay of mRNA and Ribosomal RNA during Platelet Aging and Its Correlation with Translation Activity. <i>PLoS ONE</i> , 2016, 11, e0148064.	2.5	75
36	The future of glycoprotein VI as an antithrombotic target. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 2418-2427.	3.8	70

#	ARTICLE	IF	CITATIONS
37	The class II PI 3-kinase, PI3KC2 $\beta$ , links platelet internal membrane structure to shear-dependent adhesive function. <i>Nature Communications</i> , 2015, 6, 6535.	12.8	67
38	The P2Y1 receptor is necessary for adenosine 5'-diphosphate-induced platelet aggregation. <i>Blood</i> , 1998, 92, 152-9.	1.4	63
39	Respective contributions of single and compound granule fusion to secretion by activated platelets. <i>Blood</i> , 2016, 128, 2538-2549.	1.4	59
40	Platelet Integrins in Tumor Metastasis: Do They Represent a Therapeutic Target?. <i>Cancers</i> , 2017, 9, 133.	3.7	59
41	Platelets expressing IgG receptor Fc $\gamma$ RIIA/CD32A determine the severity of experimental anaphylaxis. <i>Science Immunology</i> , 2018, 3, .	11.9	59
42	Lineage-specific overexpression of the P2Y1 receptor induces platelet hyper-reactivity in transgenic mice. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 155-163.	3.8	58
43	Importance of environmental stiffness for megakaryocyte differentiation and proplatelet formation. <i>Blood</i> , 2016, 128, 2022-2032.	1.4	58
44	Decreased Thrombotic Tendency in Mouse Models of the Bernard-Soulier Syndrome. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 241-247.	2.4	56
45	Aryl hydrocarbon receptor $\alpha$ -dependent enrichment of a megakaryocytic precursor with a high potential to produce proplatelets. <i>Blood</i> , 2016, 127, 2231-2240.	1.4	54
46	Preserved functional and biochemical characteristics of platelet components prepared with amotosalen and ultraviolet A for pathogen inactivation. <i>Transfusion</i> , 2013, 53, 1187-1200.	1.6	53
47	The P2X1 Receptor Is Required for Neutrophil Extravasation during Lipopolysaccharide-Induced Lethal Endotoxemia in Mice. <i>Journal of Immunology</i> , 2015, 194, 739-749.	0.8	49
48	Pharmacological Blockade of Glycoprotein VI Promotes Thrombus Disaggregation in the Absence of Thrombin. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 2127-2142.	2.4	48
49	Antiplatelet drugs: which targets for which treatments?. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, S313-S322.	3.8	47
50	Testing antiplatelet therapy. <i>Country Review Ukraine</i> , 2008, 10, A28-A34.	0.8	46
51	A Humanized Glycoprotein VI (GPVI) Mouse Model to Assess the Antithrombotic Efficacies of Anti-GPVI Agents. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 341, 156-163.	2.5	45
52	The role of extracellular matrix stiffness in megakaryocyte and platelet development and function. <i>American Journal of Hematology</i> , 2018, 93, 430-441.	4.1	45
53	The platelet P2 receptors in arterial thrombosis. <i>Blood Cells, Molecules, and Diseases</i> , 2006, 36, 223-227.	1.4	43
54	Myosin IIA is critical for organelle distribution and F-actin organization in megakaryocytes and platelets. <i>Blood</i> , 2014, 123, 1261-1269.	1.4	40

#	ARTICLE	IF	CITATIONS
55	A central role of GPIb-IX in the procoagulant function of platelets that is independent of the 45-kDa GPIb $\beta$ N-terminal extracellular domain. <i>Blood</i> , 2010, 116, 1157-1164.	1.4	37
56	Platelets in cancer. <i>Hamostaseologie</i> , 2015, 35, 325-336.	1.9	37
57	Platelet preparation for function testing in the laboratory and clinic: Historical and practical aspects. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 615-625.	2.3	37
58	Impact of P2Y <sub>12</sub> Inhibition by Clopidogrel on Cardiovascular Mortality in Unselected Patients Treated by Percutaneous Coronary Angioplasty. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 648-656.	2.9	36
59	Novel Function of Tenascin-C, a Matrix Protein Relevant to Atherosclerosis, in Platelet Recruitment and Activation Under Flow. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 117-124.	2.4	36
60	Fibrillar cellular fibronectin supports efficient platelet aggregation and procoagulant activity. <i>Thrombosis and Haemostasis</i> , 2015, 114, 1175-1188.	3.4	34
61	Cdc42 $\alpha$ -dependent F-actin dynamics drive structuration of the demarcation membrane system in megakaryocytes. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1268-1284.	3.8	34
62	Macrothrombocytopenia and dense granule deficiency associated with FLI1 variants: ultrastructural and pathogenic features. <i>Haematologica</i> , 2017, 102, 1006-1016.	3.5	34
63	Platelet $\alpha$ -Storage Pool Disease: An Update. <i>Journal of Clinical Medicine</i> , 2020, 9, 2508.	2.4	34
64	Desensitization of the platelet aggregation response to ADP: differential down-regulation of the P2Y <sub>1</sub> and P2cyc receptors. <i>Thrombosis and Haemostasis</i> , 2000, 84, 484-91.	3.4	32
65	Romiplostim administration shows reduced megakaryocyte response-capacity and increased myelofibrosis in a mouse model of MYH9-RD. <i>Blood</i> , 2012, 119, 3333-3341.	1.4	30
66	Hirudin and heparin enable efficient megakaryocyte differentiation of mouse bone marrow progenitors. <i>Experimental Cell Research</i> , 2012, 318, 25-32.	2.6	29
67	Targeting Platelet GPIb $\beta$ Reduces Platelet Adhesion, GPIb Signaling and Thrombin Generation and Prevents Arterial Thrombosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 1221-1229.	2.4	29
68	Characterization of Megakaryocyte Development in the Native Bone Marrow Environment. <i>Methods in Molecular Biology</i> , 2012, 788, 175-192.	0.9	28
69	Platelets are dispensable for antibody $\alpha$ -mediated transfusion $\alpha$ -related acute lung injury in the mouse. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1255-1267.	3.8	28
70	Megakaryocytes use in vivo podosome $\alpha$ -like structures working collectively to penetrate the endothelial barrier of bone marrow sinusoids. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2987-3001.	3.8	28
71	Cell surface expression of HLA I molecules as a marker of young platelets. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1511-1521.	3.8	24
72	Platelet Purinergic Receptors in Thrombosis and Inflammation. <i>Hamostaseologie</i> , 2020, 40, 145-152.	1.9	24

#	ARTICLE	IF	CITATIONS
73	Impaired inhibition of P2Y <sub>12</sub> by clopidogrel is a major determinant of cardiac death in diabetes mellitus patients treated by percutaneous coronary intervention. <i>Atherosclerosis</i> , 2011, 217, 465-472.	0.8	23
74	Inherited platelet disorders: Management of the bleeding risk. <i>Transfusion Clinique Et Biologique</i> , 2018, 25, 228-235.	0.4	23
75	Platelet transfusion: Current challenges. <i>Transfusion Clinique Et Biologique</i> , 2018, 25, 151-164.	0.4	23
76	Presence of P2X <sub>1</sub> purinoceptors in human platelets and megakaryoblastic cell lines. <i>Thrombosis and Haemostasis</i> , 1997, 78, 1500-4.	3.4	23
77	Studies of mice lacking the GPIIb/IIIa complex question the role of this receptor in atherosclerosis. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1935-1938.	3.8	19
78	Combined deficiency of RAB32 and RAB38 in the mouse mimics Hermansky-Pudlak syndrome and critically impairs thrombosis. <i>Blood Advances</i> , 2019, 3, 2368-2380.	5.2	19
79	The Antithrombotic Activity of EP224283, a Neutralizable Dual Factor Xa Inhibitor/Glycoprotein IIb/IIIa Antagonist, Exceeds That of the Coadministered Parent Compounds. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 338, 412-420.	2.5	17
80	Disrupting the platelet internal membrane via PI3K $\alpha$ inhibition impairs thrombosis independently of canonical platelet activation. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	16
81	Inherited dysfunctional platelet P2Y <sub>12</sub> receptor mutations associated with bleeding disorders. <i>Hamostaseologie</i> , 2016, 36, 279-283.	1.9	15
82	A unique microenvironment in the developing liver supports the expansion of megakaryocyte progenitors. <i>Blood Advances</i> , 2017, 1, 1854-1866.	5.2	15
83	On the Way to in vitro Platelet Production. <i>Frontiers in Medicine</i> , 2018, 5, 239.	2.6	15
84	The ATP-gated P2X <sub>1</sub> ion channel contributes to the severity of antibody-mediated Transfusion-Related Acute Lung Injury in mice. <i>Scientific Reports</i> , 2019, 9, 5159.	3.3	12
85	The PI3K $\alpha$ regulates mouse platelet membrane structure and function independently of membrane lipid composition. <i>FEBS Letters</i> , 2019, 593, 88-96.	2.8	12
86	Respective roles of Glycoprotein VI and Fc $\gamma$ RIIA in the regulation of $\alpha$ IIb $\beta$ 3-mediated platelet activation to fibrinogen, thrombus buildup, and stability. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12551.	2.3	11
87	Haemorrhagic and thrombotic diatheses in mouse models with thrombocytosis. <i>Thrombosis and Haemostasis</i> , 2015, 113, 414-425.	3.4	10
88	Removal of citrate from PAS additive solution improves functional and biochemical characteristics of buffy coat platelet concentrates stored for 7 days, with or without INTERCEPT pathogen reduction. <i>Transfusion</i> , 2021, 61, 919-930.	1.6	10
89	EP217609, a neutralisable dual-action FIIa/FXa anticoagulant, with antithrombotic effects in arterial thrombosis. <i>Thrombosis and Haemostasis</i> , 2015, 113, 385-395.	3.4	9
90	High-Resolution 3D Imaging of Megakaryocytes Using Focused Ion Beam-Scanning Electron Microscopy. <i>Methods in Molecular Biology</i> , 2018, 1812, 217-231.	0.9	9

#	ARTICLE	IF	CITATIONS
91	Functional properties of human platelets derived in vitro from CD34+ cells. <i>Scientific Reports</i> , 2020, 10, 914.	3.3	9
92	Renin-angiotensin system is involved in embryonic emergence of hematopoietic stem/progenitor cells. <i>Stem Cells</i> , 2021, 39, 636-649.	3.2	9
93	Amotosalen/UVA pathogen inactivation technology reduces platelet activability, induces apoptosis and accelerates clearance. <i>Haematologica</i> , 2017, 102, e502-e503.	3.5	8
94	Traumatic vessel injuries initiating hemostasis generate high shear conditions. <i>Blood Advances</i> , 2022, 6, 4834-4846.	5.2	8
95	On the way to in vitro platelet production. <i>Transfusion Clinique Et Biologique</i> , 2018, 25, 220-227.	0.4	7
96	Platelet P2Y12 Receptor Deletion or Pharmacological Inhibition does not Protect Mice from Sepsis or Septic Shock. <i>TH Open</i> , 2021, 05, e343-e352.	1.4	7
97	P2Y receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. <i>IUPHAR/BPS Guide To Pharmacology CITE</i> , 2019, 2019, .	0.2	6
98	Use of electron microscopy to study megakaryocytes. <i>Platelets</i> , 2020, 31, 589-598.	2.3	5
99	Platelet Fc $\gamma$ R1A-induced serotonin release exacerbates the severity of transfusion-related acute lung injury in mice. <i>Blood Advances</i> , 2021, 5, 4817-4830.	5.2	5
100	Î-storage pool disease: an underestimated cause of unexplained bleeding. <i>Hematologie</i> , 2017, 23, 243-254.	0.0	4
101	Differential Role of Glycoprotein VI in Mouse and Human Thrombus Progression and Stability. <i>Thrombosis and Haemostasis</i> , 2021, 121, 543-546.	3.4	4
102	Human platelets labeled at two discrete biotin densities are functional in vitro and are detected in vivo in the murine circulation: A promising approach to monitor platelet survival in vivo in clinical research. <i>Transfusion</i> , 2021, 61, 1642-1653.	1.6	4
103	P2Y receptors in GtoPdb v.2021.3. <i>IUPHAR/BPS Guide To Pharmacology CITE</i> , 2021, 2021, .	0.2	3
104	Transfusion of fresh washed platelets does not prevent experimental polymicrobial-induced septic shock in mice. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 449-460.	3.8	3
105	Dehydration of blood platelets by zeodration: in vitro characterization and hemostatic properties in vivo. <i>Transfusion</i> , 2015, 55, 2207-2218.	1.6	2
106	A gain-of-function variant in the Wiskott-Aldrich syndrome gene is associated with a MYH9-related disease-like syndrome. <i>Blood Advances</i> , 2022, 6, 5279-5284.	5.2	2
107	AHR:IKAROS Interaction Promotes Platelet Biogenesis in Response to SR1. <i>Reports</i> , 2021, 4, 7.	0.5	1
108	CDX2 regulates ACE expression in blood development and leukemia cells. <i>Blood Advances</i> , 2021, 5, 2012-2016.	5.2	1

#	ARTICLE	IF	CITATIONS
109	Physiopathologie de l'anaphylaxie aux curares. Le futur et le possible: les plaquettes. Revue Francaise D'allergologie, 2018, 58, 201-202.	0.2	0
110	Platelets: A more than a centenary old Odyssey and more to come. Transfusion Clinique Et Biologique, 2018, 25, 149-150.	0.4	0